Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A

2(50.0%)

Phase 2

1(25.0%)

Phase 3

1(25.0%)

4Total

N/A(2)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05197322Phase 2Recruiting

NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer

Role: collaborator

NCT05432739Recruiting

Nodule IMmunophenotyping Biomarker for Lung Cancer Early Diagnosis Study

Role: collaborator

NCT01114776Completed

Multi-Center Study of Iron Overload: Pilot Study

Role: collaborator

NCT01913548Completed

Multi-Center Study of Iron Overload: Survey Study (MCSIO)

Role: collaborator

NCT03980587Unknown

Exploratory Study of Molecular Characterization in Patients With Metastatic Germ Cell Tumours Refractory/Resistant to Platinum Treatment

Role: collaborator

NCT02116504Not ApplicableUnknown

Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients

Role: collaborator

NCT00025090Phase 3Completed

Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer

Role: lead

NCT01254591Not ApplicableUnknown

Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer

Role: lead

All 8 trials loaded